Following the company’s statement that the U.S. Food and Drug Administration (FDA) has approved its Bortezomib injection under New Drug Application (NDA) 212782, Shilpa Medicare Ltd.’s stock price increased by 9.12% this week.
Bortezomib is an important therapeutic agent for the treatment of multiple myeloma and certain types of lymphoma. The FDA approval is likely to strengthen Shilpa Medicare’s position in the oncology industry, as the business seeks to deliver affordable and efficient treatment options.
The successful approval confirms Shilpa Medicare’s commitment to quality and innovation, opening the way for possible collaborations and increased market share in the US pharmaceutical industry.
Stock Performance on Friday
– Open: ₹751.00
– High: ₹774.80
– Low: ₹724.80
TOPICS:
Shilpa Medicare